Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential Novel Non-Biologic Therapy in Treating Inflammatory Bowel Disease
BEVERLY, Mass., March 16, 2017 (GLOBE NEWSWIRE) — Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to inform shareholders that, next week, the Company will be providing additional detailed data from its ongoing Phase 2a Proof-of-Concept (PoC) study of Brilacidin for... Read More →
Ultrafast Lasers Global Market Growing Ultrafast
Wellesley, Mass, March 16, 2017 (GLOBE NEWSWIRE) — New proprietary research by BCC Research reveals that governmental mandates promoting laser marking in the industrial sector and the increasing demand for minimally invasive surgeries in the health care sector are boosting huge growth in the global market for ultrafast lasers. From 2016-2021, this ultrafast-growing market should... Read More →
Trans World Entertainment Announces Annual and Fourth Quarter Results
ALBANY, N.Y., March 16, 2017 (GLOBE NEWSWIRE) — Trans World Entertainment Corporation (Nasdaq:TWMC) today reported financial results for the 13 (“Fourth Quarter”) and 52 week periods (“Fiscal 2016”) ended January 28, 2017. “Our results demonstrate the importance, benefit and potential of our acquisition of etailz. Trans World’s sales growth is directly attributable to the diversification... Read More →
KemPharm Presents Clinical Data for Opioid Prodrug Candidates at American Academy of Pain Medicine’s Annual Meeting
Poster Presentations Highlight Oral Equivalency and Intranasal Abuse Deterrence Technology CORALVILLE, Iowa, March 16, 2017 (GLOBE NEWSWIRE) — KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, presented clinical data from two of its opioid prodrug candidates, KP511, KemPharm’s prodrug of hydromorphone, and KP201/IR, KemPharm’s prodrug of... Read More →
Polyurea Market worth over $1.5bn by 2022: Global Market Insights Inc.
Ocean View, Delaware, March 16, 2017 (GLOBE NEWSWIRE) — The research study report “Polyurea Market Size By Product (Lining, Coating, Sealants), By Raw Material (Aliphatic, Aromatic), By Application (Industrial, Construction, Transportation), Industry Analysis Report, Regional Outlook, Application Potential, Price Trend, Competitive Market Share & Forecast, 2015 – 2022” by Global Market Insights, Inc. says Polyurea... Read More →
Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial
– Efficacy endpoints reordered and co-primary endpoints established –– Ongoing trial, if successful, expected to serve as single pivotal study for BLA submission – – Conference Call Scheduled for 8:00 AM ET – WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) — Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs... Read More →
Generic Drugs to Slow Growth of Antifungal Market
Wellesley, Mass, March 16, 2017 (GLOBE NEWSWIRE) — New proprietary research by BCC Research predicts that new and innovative antifungal drugs in development, along with a growing number of people with weakened immune systems and FDA fast-track provisions, are aiding growth in the global market for antifungal drugs. BCC Research’s Antifungal Drugs: Technologies and Global... Read More →
Defense Stock Roundup: North Korea-US Missile Rift Hits Stocks; LMT, NOC Win Deals; OA Lags Earnings
Last week, the Aerospace-Defense sector was weighed down by the cross-border missile power tussle between North Korea and the U.S. Notably, the battle was sparked when North Korea fired four ballistic missiles into the waters off its east coast on Mar 6. What analysts had initially suspected was later confirmed by North Korea’s media that... Read More →
Opiant Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., March 16, 2017 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the fiscal second quarter ended January 31, 2017 and provided an update on recent developments and upcoming milestones. “Since the beginning of our fiscal second... Read More →
Virtu Releases Statement
NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) — Virtu Financial, Inc. (NASDAQ:VIRT) a leading technology-enabled market maker and liquidity provider to the global financial markets, today released the following statement: “While we typically do not as a matter of policy comment about Virtu’s merger and acquisition activities, following yesterday’s press release by KCG Holdings, Inc. we... Read More →